24 / 24
Page 66
Journal of Pharmaceutical care and Health Systems | ISSN: 2376-0419 | Volume 5
Pharmaceutical sciences
11
th
World Congress on
September 28-29, 2018 | Montreal, Canada
Sulfated-modified
Cordia myxa
gum as sustained-release and mucoadhesive excipient in Losartan
Potassium tablet formulation
Sonia Dhiman
1
, Ashok Kumar Tiwary
2
and
Sandeep Arora
1
1
Chitkara University, India
2
Punjabi University, India
N
ative gums may be limited in function, but modification may improve their activity. The objective of the present study was to
evaluate native and modified form of
Cordia myxa
gum for its sustained release and mucoadhesive properties. Modification
of natural
Cordia myxa
polysaccharide was done using sulfation technique. The modified polymer was evaluated for mucoadhesive
characteristics with systematic optimization by central composite experimental designing. The tablets prepared with modified
polymer were compared with native polymer and Carbopol 934. The mucoadhesive tablets of Losartan Potassium were evaluated for
various parameters such as weight variation, hardness, friability, drug content, content uniformity, mucoadhesion strength,
in vitro
release characteristics and
in vivo
gastric retention study. Modification improved the gum's flow properties, resulting in Carr's index
and Hausner's ratio lower than 15% and 1.25, respectively. Swelling studies showed that modified gum had lower water absorption
capacity and swelling index values while packing properties improved upon sulfation, indicated by lower tapped density values.
Modification of the gum was confirmed by FTIR, DSC and 1H NMR. The gum's mucoadhesive properties were improved and
sustained release action of 24 h was obtained. Sulfation of native
Cordia myxa
gum improved the flow, mechanical and sustained-
release properties of Losartan Potassium tablets. The results suggested that sulfation of
Cordia myxa
gum proved to be a successfully
employed method for formulation of mucoadhesive drug delivery systems to alleviate the drawbacks of the conventional delivery of
the drugs in the management of hypertension thereby improving the patient compliance.
J Pharma Care Health Sys 2018, Volume 5
DOI: 10.4172/2376-0419-C3-033